141 related articles for article (PubMed ID: 19077269)
1. Epithelial ovarian cancer relapsing as isolated lymph node disease: natural history and clinical outcome.
Legge F; Petrillo M; Adamo V; Pisconti S; Scambia G; Ferrandina G
BMC Cancer; 2008 Dec; 8():367. PubMed ID: 19077269
[TBL] [Abstract][Full Text] [Related]
2. Isolated lymph node recurrence in epithelial ovarian cancer: Recurrence with better prognosis?
Delangle R; Rossard L; Cirier J; Delvallée J; Bendifallah S; Touboul C; Collinet P; Coutant C; Akladios C; Lavoué V; Bolze PA; Huchon C; Bricou A; Canlorbe G; Ballester M; Darai E; Body G; Ouldamer L;
Eur J Obstet Gynecol Reprod Biol; 2020 Jun; 249():64-69. PubMed ID: 32381349
[TBL] [Abstract][Full Text] [Related]
3. Isolated lymph node relapse of epithelial ovarian carcinoma: outcomes and prognostic factors.
Blanchard P; Plantade A; Pagès C; Afchain P; Louvet C; Tournigand C; de Gramont A
Gynecol Oncol; 2007 Jan; 104(1):41-5. PubMed ID: 16952391
[TBL] [Abstract][Full Text] [Related]
4. Secondary cytoreductive surgery for isolated lymph node recurrence of epithelial ovarian cancer: a multicenter study.
Ferrero A; Ditto A; Giorda G; Gadducci A; Greggi S; Daniele A; Fuso L; Panuccio E; Scaffa C; Raspagliesi F; Sismondi P; Biglia N
Eur J Surg Oncol; 2014 Jul; 40(7):891-8. PubMed ID: 24378007
[TBL] [Abstract][Full Text] [Related]
5. Salvage lymphadenectomy in recurrent ovarian cancer patients: Analysis of clinical outcome and BRCA1/2 gene mutational status.
Gallotta V; Bruno M; Conte C; Giudice MT; Davià F; Moro F; Zannoni GF; Fagotti A; De Bonis M; Capoluongo E; Scambia G; Ferrandina G
Eur J Surg Oncol; 2020 Jul; 46(7):1327-1333. PubMed ID: 32085925
[TBL] [Abstract][Full Text] [Related]
6. Retroperitoneal lymph node recurrence of epithelial ovarian cancer: Prognostic factors and treatment outcome.
Levy T; Migdan Z; Aleohin N; Ben-Shem ; Peled O; Tal O; Elyashiv O
Gynecol Oncol; 2020 May; 157(2):392-397. PubMed ID: 32151375
[TBL] [Abstract][Full Text] [Related]
7. Survival outcomes of ovarian cancer patients treated with secondary cytoreductive surgery for isolated lymph node recurrence: A systematic review of the literature.
Pergialiotis V; Androutsou A; Papoutsi E; Bellos I; Thomakos N; Haidopoulos D; Rodolakis A
Int J Surg; 2019 Sep; 69():61-66. PubMed ID: 31362125
[TBL] [Abstract][Full Text] [Related]
8. [Treatment and prognostic analysis of ovarian cancer patients with isolated region of lymph node recurrence].
Tu H; Huang H; Huang QD; Li Z; Feng YL; Liu JH
Zhonghua Fu Chan Ke Za Zhi; 2012 Dec; 47(12):928-33. PubMed ID: 23324194
[TBL] [Abstract][Full Text] [Related]
9. Ovarian cancer patients with localized relapse: clinical outcome and prognostic factors.
Petrillo M; Fagotti A; Ferrandina G; Fanfani F; Costantini B; Vizzielli G; Pedone Anchora L; Nero C; Margariti PA; Scambia G
Gynecol Oncol; 2013 Oct; 131(1):36-41. PubMed ID: 23791829
[TBL] [Abstract][Full Text] [Related]
10. Clinical features and outcomes of neck lymphatic metastasis in ovarian epithelial carcinoma.
Chen CW; Torng PL; Chen CL; Chen CA
World J Surg Oncol; 2013 Oct; 11():255. PubMed ID: 24088247
[TBL] [Abstract][Full Text] [Related]
11. Quantitative metabolic parameters measured on F-18 FDG PET/CT predict survival after relapse in patients with relapsed epithelial ovarian cancer.
Kim CY; Jeong SY; Chong GO; Son SH; Jung JH; Kim DH; Lee SW; Ahn BC; Lee J
Gynecol Oncol; 2015 Mar; 136(3):498-504. PubMed ID: 25557270
[TBL] [Abstract][Full Text] [Related]
12. Prognostic impact of celiac lymph node involvement in patients after frontline treatment for advanced ovarian cancer.
Angeles MA; Ferron G; Cabarrou B; Balague G; Martínez-Gómez C; Gladieff L; Pomel C; Martinez A
Eur J Surg Oncol; 2019 Aug; 45(8):1410-1416. PubMed ID: 30857876
[TBL] [Abstract][Full Text] [Related]
13. Outcomes and patterns of secondary relapse in platinum-sensitive ovarian cancer: implications for tertiary cytoreductive surgery.
Tang J; Liu DL; Shu S; Tian WJ; Liu Y; Zang RY
Eur J Surg Oncol; 2013 Jul; 39(7):786-91. PubMed ID: 23490332
[TBL] [Abstract][Full Text] [Related]
14. Impact of lymph node ratio on survival in stage III ovarian high-grade serous cancer: a Turkish Gynecologic Oncology Group study.
Ayhan A; Ozkan NT; Sarı ME; Celik H; Dede M; Akbayır Ö; Güngördük K; Şahin H; Haberal A; Güngör T; Arvas M; Meydanlı MM
J Gynecol Oncol; 2018 Jan; 29(1):e12. PubMed ID: 29185270
[TBL] [Abstract][Full Text] [Related]
15. Can pattern and depth of invasion predict lymph node relapse and prognosis in tongue squamous cell carcinoma.
Wu K; Wei J; Liu Z; Yu B; Yang X; Zhang C; Abdelrehem A; Zhang C; Li S
BMC Cancer; 2019 Jul; 19(1):714. PubMed ID: 31324174
[TBL] [Abstract][Full Text] [Related]
16. The clinical outcome of epithelial ovarian cancer patients with apparently isolated lymph node recurrence: a multicenter retrospective Italian study.
Gadducci A; Cosio S; Zola P; Sostegni B; Ferrero AM; Teti G; Cristofani R; Sartori E
Gynecol Oncol; 2010 Mar; 116(3):358-63. PubMed ID: 19954826
[TBL] [Abstract][Full Text] [Related]
17. Mesenteric lymph node involvement in advanced ovarian cancer patients undergoing rectosigmoid resection: prognostic role and clinical considerations.
Gallotta V; Fanfani F; Fagotti A; Chiantera V; Legge F; Gueli Alletti S; Nero C; Margariti AP; Papa V; Alfieri S; Ciccarone F; Scambia G; Ferrandina G
Ann Surg Oncol; 2014 Jul; 21(7):2369-75. PubMed ID: 24558070
[TBL] [Abstract][Full Text] [Related]
18. Clinical and molecular characterization of ovarian carcinoma displaying isolated lymph node relapse.
Hollis RL; Carmichael J; Meynert AM; Churchman M; Hallas-Potts A; Rye T; MacKean M; Nussey F; Semple CA; Herrington CS; Gourley C
Am J Obstet Gynecol; 2019 Sep; 221(3):245.e1-245.e15. PubMed ID: 31055034
[TBL] [Abstract][Full Text] [Related]
19. Secondary cytoreductive surgery in patients presenting with isolated nodal recurrence of epithelial ovarian cancer.
Fotiou S; Aliki T; Petros Z; Ioanna S; Konstantinos V; Vasiliki M; George C
Gynecol Oncol; 2009 Aug; 114(2):178-82. PubMed ID: 19450872
[TBL] [Abstract][Full Text] [Related]
20. Prognostic factors of overall survival for patients with FIGO stage IIIc or IVa ovarian cancer treated with neo-adjuvant chemotherapy followed by interval debulking surgery: A multicenter cohort analysis from the FRANCOGYN study group.
Vincent L; Jankowski C; Ouldamer L; Ballester M; Bendifallah S; Bolze PA; Akladios C; Costaz H; Lavoué V; Canlorbe G; Collinet P; Touboul C; Huchon C; Bricou A; Dridi S; Padéano MM; Bengrine L; Arnould L; Coutant C;
Eur J Surg Oncol; 2020 Sep; 46(9):1689-1696. PubMed ID: 32417154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
